Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma

Leukemia & Lymphoma
Asher Chanan-KhanPhilip McCarthy

Abstract

Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with alpha/beta HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.

References

Jun 23, 2001·The American Journal of Surgical Pathology·S KumarE S Jaffe

❮ Previous
Next ❯

Citations

Mar 11, 2010·International Journal of Clinical Oncology·Yuya NagaiTakayuki Takahashi
Apr 25, 2012·International Journal of Hematology·Armin RashidiStephen I Fisher
Mar 22, 2005·Bone Marrow Transplantation·M R MansourK S Peggs
Apr 8, 2006·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Vít ProcházkaDavid Starostka
Dec 3, 2010·Journal of Crohn's & Colitis·Anne Thai, Thomas Prindiville
Jan 29, 2014·Seminars in Hematology·Nishitha M Reddy, Andrew M Evens
Apr 24, 2007·European Journal of Internal Medicine·H J MeulenbeldG J Creemers
Jan 2, 2007·Cancer Letters·Amit W Panwalkar, James O Armitage
Apr 13, 2011·British Journal of Haematology·Claire E DeardenUNKNOWN British Committee for Standards in Haematology
Aug 27, 2014·European Journal of Haematology·Marco Foppoli, Andrés J M Ferreri
Jun 6, 2015·Blood Cancer Journal·A Rashidi, A F Cashen
Jul 24, 2013·Clinical Lymphoma, Myeloma & Leukemia·Koppany VisnyeiIlan Shapira
Aug 30, 2013·The Cochrane Database of Systematic Reviews·Max SchlaakPeter Kurschat
Oct 8, 2005·Blood·Mujahid A RizviSteven T Rosen
Aug 7, 2020·Blood·Barbara ProAmir Behdad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.